Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 14, 2025
Daily News
April 14, 2025
- Servier Poised to Double Japan Workforce over Next 3 Years: CEO, Local Chief
April 14, 2025
- Chugai’s DMD Gene Therapy Up for Japan Panel Review on April 18
April 14, 2025
- MHLW Panel to Review Moderna’s RSV Jab, GSK’s ADC, and More on April 21
April 14, 2025
- Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
- Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
April 14, 2025
- RaQualia Ends Tamibarotene License Pact with Syros
April 14, 2025
- JGA to Release Interim Report on Industry Revamp in June: President
April 14, 2025
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…